Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Nevada for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Nevada only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Nevada (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Subramanyeswara Arekapudi (NPI 1366671943)

Field	Value
Entity Type	Individual
Organization	Subramanyeswara Arekapudi
Address	5423 Reno Corporate Dr
City	Reno
State	NV
ZIP	89511
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	July 5, 2009

Payer Source	Total Paid
Medicare	$1.7M
Medicaid	$0

Key Findings

This provider’s billings are effectively single‑payer: total Medicare revenue is $1.7M and there is no Medicaid billing on file, so Medicaid is not a material contributor to this practice’s payer mix. The absence of any Medicaid activity means the provider’s revenue profile and utilization patterns are driven almost entirely by Medicare beneficiaries and Medicare reimbursements.

Revenue is highly concentrated in a small set of infused oncology agents: the top 3 Medicare codes (J9271, J9299, J9144) account for 72.7% of the provider’s total Medicare revenue. Individually those codes represent 32.9% (J9271), 20.0% (J9299), and 19.8% (J9144) of Medicare revenue, indicating dependence on high‑cost immunotherapy and monoclonal antibody infusions.

The procedure mix and top codes indicate an infusion‑centric hematology/oncology practice. High revenue from drug codes such as J9271 (pembrolizumab), J9299 (nivolumab), and J9144 (daratumumab) combined with chemotherapy administration codes (96413, 96401, G0498) and supportive biologics (Q5111, J0897) point to in‑office delivery of complex oncology infusions and routine supportive care. This pattern is consistent with a clinic that operates an infusion suite and manages ongoing systemic therapy.

On competitive standing for the primary biologic agents, this provider is a modest national participant rather than a dominant supplier: J9271 ranks in the 54th percentile, J9299 in the 48th percentile, and J9144 in the 55th percentile nationally, each labeled in the source as “typical, unremarkable volume.” Those mid‑percentile ranks suggest routine provision of these agents but not market leadership in their use.

Outpatient evaluation-and-management activity is comparatively elevated: 99214 is reported as “notably above typical national volume” (98th percentile) and 99215 is also “notably above typical national volume” (96th percentile). The above‑typical E/M volumes (99214 revenue $98.7K; 99215 revenue $39.7K) imply substantial ongoing medical management and follow‑up care of complex patients in the clinic setting.

Certain support and access procedures show unusually high relative use: 96523 (irrigation of venous access device) is flagged “notably above typical national volume” (96th percentile), and 36415 (routine venipuncture) appears at a high percentile (97th) though its label in the file is “typical, unremarkable volume.” Together these codes underscore steady procedural throughput tied to infusion services and vascular access maintenance.

The provider’s tenure is long enough to be considered established: the NPI was enumerated on 2009-07-05 (~17 years ago). This multi‑year presence combined with concentrated oncology infusion revenue suggests operational continuity in chemotherapy/immunotherapy delivery rather than a newly launched infusion practice.

From a business risk and operational perspective, the provider’s Medicare concentration and the fact that 72.7% of Medicare revenue is driven by three drugs exposes the practice to shifts in utilization patterns, reimbursement changes, or formulary management for those agents. Because there is no Medicaid billing on file, any Medicare policy changes would likely have an outsized impact on the practice’s overall revenue base.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

56 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	13,200	$40	$567.6K
J9299	Injection, nivolumab, 1 mg	14,400	$20	$345.6K
J9144	Injection, daratumumab, 10 mg and hyaluronidase‑fihj	9,000	$40	$342K
J0897	Injection, denosumab, 1 mg	5,760	$20	$103.7K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	1,000	$100	$98.7K
Q5111	Injection, pegfilgrastim-cbqv (udenyca), biosimilar, 0.5 mg	730	$110	$77.6K
99215	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the…	290	$140	$39.7K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	320	$100	$32.7K
J9041	Injection, bortezomib, 0.1 mg	3,150	$10	$15.8K
99213	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the…	220	$70	$15.3K

Showing 1–10 of 56

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 56 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Nevada Distribution

Subramanyeswara Arekapudi — 3 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Nevada

Full comparison — all codes billed, vs. state median

56 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	17	40	13,000	$40	$625.8K
J9144	7	10	9,180	$40	$445.4K
J9299	5	10	14,400	$20	$362K
J0897	19	70	3,630	$20	$94.6K
Q5111	1	10	400	$110	$46.4K
99233	693	1,150	150	$90	$26.8K
96413	21	70	210	$100	$23.7K
84443	52	80	50	$20	$22.7K
80053	45	100	160	$10	$22.2K
99214	117	3,610	110	$80	$19K

Showing 1–10 of 56

Related Providers

Other providers that share a Tax Identification Number (TIN) with Subramanyeswara Arekapudi, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Marshall Medical Center	CA	General Acute Care Hospital	$0	$33.8M
Tejvir Singh	NV	Hematology & Oncology Physician	$2.5M	$280
Santhosh Ambika	NV	Hematology & Oncology Physician	$1.9M	$1.6K
Emily Guerard	NV	Hematology & Oncology Physician	$1.3M	$0
Sowjanya Reganti	NV	Hematology & Oncology Physician	$1.3M	$5.3K
Chivonne Harrigal	CA	Diagnostic Radiology Physician	$1.3M	$1.1K
Juan Cattoni	NV	Hematology & Oncology Physician	$1.2M	$240
Vodur Reddy	NV	Hematology & Oncology Physician	$1M	$0
Ghulam Thaver	AL	Diagnostic Radiology Physician	$444.7K	$0
Garth Tormoen	NV	Radiation Oncology Physician	$321K	$0

Nearby Providers

Other providers in the same ZIP code as Subramanyeswara Arekapudi, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Kuhn Physical Therapy LLC	NV	Physical Therapist	$0	$13.1M
Elena Geraymovych	NV	Ophthalmology Physician	$4.1M	$16.9K
Routt Dialysis LLC	NV	End-Stage Renal Disease (ESRD) Treatment Clinic/Center	$0	$3.6M
Nevada Emergency Physicians PLLC	NV	Emergency Medicine Physician	$0	$3.3M
Eye Surgery Center Of Northern Nevada, LLC	NV	Ambulatory Surgical Clinic/Center	$2.7M	$114.7K
Steven Friedlander	NV	Ophthalmology Physician	$2.4M	$376.5K
Culpepper Psychiatric Associates PLLC	NV	Community Health Clinic/Center	$0	$2.6M
Liberty Dialysis-south Reno LLC	NV	End-Stage Renal Disease (ESRD) Treatment Clinic/Center	$0	$2.5M
Saint Marys Urgent Care LLC	NV	Multi-Specialty Clinic/Center	$0	$2.3M
Bennett Medical Services	NV	Oxygen Equipment & Supplies (DME)	$0	$2.1M

Subramanyeswara Arekapudi — Billing Profile & Reimbursement Data

Sign up for Subramanyeswara Arekapudi — Billing Profile & Reimbursement Data policy alerts

Subramanyeswara Arekapudi — Billing Profile & Reimbursement Data

Sign up for Subramanyeswara Arekapudi — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References